<DOC>
	<DOCNO>NCT01056822</DOCNO>
	<brief_summary>Multicenter , Randomized , Open-label Study Assess Whether Treatment With Mycophenolate sodium ( MPS ) Allows Higher Dose Optimization Versus Mycophenolate mofetil ( MMF ) Leading Dose Reduction Tacrolimus . Maximiza Study .</brief_summary>
	<brief_title>Multicenter , Randomized , Open-label Study Assess Whether Treatment With Mycophenolate Sodium ( MPS ) Allows Higher Dose Optimization Versus Mycophenolate Mofetil ( MMF ) Leading Dose Reduction Tacrolimus . Maximiza Study .</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion 1 . Renal transplant recipient ≥ 1 year ≤ 5 year prior1 inclusion study . 2 . Patients receive immunosuppressive regimen include MMF ≤1000 mg/day ≥ 250 mg/day 4 Prograf®1 Advagraf®6 ( level ≥7 ng/ml ) . 3 . Patients receive current maintenance immunosuppressive regimen stable dos MMF least past 3 months.2 4 . Patients include must Prograf® Advagraf® level ≥ 7ng/ml4 least one month prior inclusion trial.2 5 . Patients low immunological risk , investigator 's opinion . 6 . Patients estimate glomerular filtration rate base MDRD formula &gt; 30 ml/min x 1.73 m2.1 7 . Patients 18 year age.1 8 . Patients able understand study information give write informed consent . 9 . Patients able meet study requirement , include complete questionnaire attend study visit . Exclusion criteria 1 . Patients GI symptom know assume cause mycophenolic acid ( MPA ) treatment ( e.g . oral bisphosphonateinduced infectious diarrhoea ) . 2 . Patients chronic inflammatory bowel disease . 3 . Diabetic patient . 4 . Acute rejection &lt; 1 month prior inclusion study . 5 . Patients leukopenia ( &lt; 3500 cells/mm3 ) thrombocytopenia ( &lt; 100,000 cells/mm3 ) . 6 . Women childbearing potential planning become pregnant , pregnant and/or breastfeeding , wish use effective contraception [ hormonal contraceptive ( implantation , patch , oral ) doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , contraceptive sponge , cervical cap ) ] . 7 . Presence psychiatric illness ( schizophrenia , major depression ) , investigator 's opinion , could interfere study requirement . 8 . Patients undergo surgery acute condition hospitalise . 9 . Any medical condition , investigator 's opinion base blood count chart review , could interfere completion study , include limited visual problem cognitive impairment . 10 . Patients receive receive investigational medicinal product 30 day prior inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>